Anke Wixmerten

University of Basel

Papers

1

Total Citations

13

H-Index

1

About

Anke Wixmerten is a leading researcher in the field of Advanced Therapy Medicinal Products (ATMPs), with a specific focus on the scalable manufacturing of tissue-engineered cartilage. Her work directly addresses one of the most critical bottlenecks in regenerative medicine: transitioning from laboratory-scale production to robust, automated, and cost-effective mass production for clinical trials. In her highly cited 2021 paper, "From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product" (13 citations), she pioneered a platform design concept that outlines the essential automation steps for manufacturing a cartilage product ready for Phase II trials. This contribution is pivotal for bridging the gap between promising preclinical results and real-world patient access. By tackling the engineering and regulatory challenges of ATMP commercialization, Wixmerten is helping to unlock the potential of tissue engineering for chronic and progressive diseases that currently lack satisfactory treatments, making her a key figure in the future of personalized regenerative medicine.

Research Focus

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product
13 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: University of Basel

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago